Anti-Breast Cancer Compound Library

Cat. No. : CS-L074 (1740 compounds)
Library Contents: PDF | SDF

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 1740 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Size (Pre-dissolved DMSO or Solid) Stock Price
30 μL/well (10 mM solution) In-stock Get quote
50 μL/well (10 mM solution) In-stock Get quote
100 μL/well (10 mM solution) In-stock Get quote
250 μL/well (10 mM solution) In-stock Get quote
Products are for research use only. Not for human use. We do not sell to patients.

Bulk Inquiry

Collapse
Your information is safe with us. * Required Fields
  Salutation:
* Country or Region:
* Applicant name:
* Organization Name:
* Email address:
* Requested quantity:
* Phone number:
  Remarks:
 
Please slide the slider!
>>
 
Name, 
Organization name, 
Email address, 
Requested quantity, 
Phone number, 

Request SDF File

x

Please enter your email address. We will send your requested SDF file to you as soon as possible.

  • Data Sheet

  • Description & Advantages

  • Composition

  • Contents

Formulation:A collection of 1740 small molecules with anti-breast cancer activity supplied as pre-dissolved Solutions or Solid
Container:96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
Storage:-80°C
Shipping:Blue ice

•   A unique collection of 1740 compounds with identified and potential anti-breast cancer activity for high throughput screening (HTS) and high content screening (HCS).

•   Targets include kinases, cell cycle key components, tumorigenesis related signaling pathways, popular targets in breast cancer, and more.

•   A useful tool for the discovery of anti-breast cancer drugs.

•   Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.

•   Structurally diverse, medicinally active, and cell permeable.

•   Detailed compound information with structure, IC50, and brief introduction.

•   Validated NMR and HPLC to ensure high purity and quality.

•   All compounds are in stock and continuously updated.

PDF
Browsing History

    Customize Your Library

    You can select:
    • Specific Compounds
    • Quantities
    • Plate map
    • Concentration
    • Format (Solid or DMSO Solution)

    Please contact us at sales@chemscene.com

    Recommend Products
    CS-L036P Cat. No. : CS-L036P

    (2966 compounds)

    Covalent Screening Library Plus

    CS-L141 Cat. No. : CS-L141

    (2450 compounds)

    Off-patent Drug Library

    CS-L083 Cat. No. : CS-L083

    (1815 compounds)

    Anti-Cancer Metabolism Compound Library